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Apart of CF, CFTR gene mutations have also been associated with CFTR-related
disorders, such as congenital absence of the vas deferens (CAVD). The most
common CAVD mutation is the IVS8(T)5 variant in CFTR gene intron 8 that
alters the efﬁciency with which the splice acceptor is used. The aim of the present
study was to analyze and compare the levels of CFTR mRNA transcripts lacking
exon 9 obtained from testicular and nasal biopsies of CAVD patients.
A total of 23 testicular biopsies were analyzed: 12 from CAVD and 10 from patients
with conserved spermatogenesis (controls). In 4 CAVD patients, nasal biopsies
were also analyzed. The relative amounts of accurately spliced transcripts (+9) and
transcripts lacking exon 9 (−9) were evaluated by real-time PCR, using a multiplex
based assay (TaqMan).
We detected in all samples the presence of the 2 CFTR transcripts, +9 and
−9. However, patients carrying IVS8(T)5 variant produced higher proportions of
transcripts −9 than patients carrying the IVS8(T)7 or IVS8(T)9. Additionally, it
was observed that the proportion of transcripts −9 was higher in testicular biopsies
than in the nasal epithelium of the same patient.
As previously reported, we conﬁrmed that the degree of CFTR exon 9 skipping was
inversely correlated with the IVS8(T)n polymorphic tract. Moreover, the level of
CFTR mRNA transcripts lacking exon 9 was increased in testicular biopsies when
compared with nasal biopsies from the same individual. Thus, differential efﬁciency
between different tissues expressing CFTR may explain the reproductive tract
abnormalities, such as CAVD observed in our patients, and absence of pathologic
changes in other CF-associated organs.
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Background: Hyperechogenic bowel (HB) is deﬁned as a fetal bowel with
equivalent brightness to the iliac crests, occuring in 0.1−1.8% of pregnancies.
It is an echographic marker of fetuses at increased risk for cystic ﬁbrosis (CF),
chromosomopathies and fetal infection. Association with other anomalies may
enable recognition of a syndrome. It can be a normal variant (65%) or a consequence
of intraamniotic bleeding.
Objective: To performe a retrospective analysis (2005–2009) of CFTR gene analysis
in fetuses with HB, refered to our center.
Methods: Clinical cases were selected from clinical and laboratory databases,
using the terms “hyperechogenic bowel” and “echographic marker”. Clinical data
included family history, second trimester ultrasound examination, CFTR gene
screening, fetal karyotype, maternal and/or fetal serologies (toxoplasmosis, rubella
and cytomegalovirus), and pregnancy outcome. Genetic counselling was performed
in all cases.
Results: Family history was irrelevant in all 27 cases. Isolated HB ocurred in
24 cases (88.9%), and association to pielic dilatation in 3 cases. CFTR gene analysis
identiﬁed 1 carrier couple of the mutation F508del, and their homozygotic fetus
(3.7%). Two other carriers of mutations G542X and G576A were identiﬁed. 1 fetus
had a 47,XY,+21 karyotype (3.7%) and concurrently a cytomegalovirus infection
(3.7%). No other infections were observed. Follow-up in 7 cases (25.9%) was
known: 5 healthy newborns and 2 terminations of pregnancy.
Discussion: HB is a signiﬁcant echographic marker that should be evaluated in
the context of genetic counselling since it can lead to the identiﬁcation of affected
fetuses and carrier status for CF.
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We have previously demonstrated that adult and newborn cystic ﬁbrosis (CF) mice
exhibit tracheal cartilage ring abnormalities (Bonvin et al., 2008). In the present
study, we explored two different molecular mechanisms possibly involved in these
congenital malformations based on (1) the inﬂuence of secondary genetic factors
during airway development, (2) a reduction in Cl− secretion into the fetal lung
liquid. We investigated the expression of the TRAF4 gene which is required for
normal development of the trachea, and the TMEM16a gene, a dominant calcium-
activated Cl− channel in mouse airways, which is expressed in tracheal epithelium
and smooth muscle. The expression level of these two genes was examined by qPCR
in total embryos and ex-vivo tracheas at embryonic stage E15 in Cftr knockout and
F508del-CFTR mice and their respective controls.
Our data show a lower expression of TRAF4 mRNA in embryos and tracheas at E15
in the two CF mice compared to their controls. We also found that the expression of
TMEM16a mRNA is similar in total embryos of CF mice as compared to controls,
but is signiﬁcantly larger in tracheas alone. These results support the hypothesis that
TRAF4 should play a role in the occurrence of tracheal abnormalities and suggest
that TMEM16a may provide a parallel route for Cl− secretion for trachea that lack
CFTR although this effect is insufﬁcient to avoid cartilage defects. Our present
ﬁndings prompt us to investigate further the role of these two genes in congenital
malformations of the trachea within the context of CFTR protein dysfunction.
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One possible target for drug discovery aiming at treating Cystic Fibrosis is to
correct the ionic imbalance through stimulation of alternative ionic pathway that
may compensate the deﬁcient CFTR dependent Cl− secretion. In previous studies,
we identiﬁed guanabenz as an activator of Ca2+ dependent Cl− channel (CaCC)
via a Ca2+ inﬂux in human CF nasal (CF15) and tracheal (CF-KM4) epithelial cell
lines and in freshly isolated CF and non CF human ciliated epithelial cells. Here,
we explored the molecular mechanism of Ca2+ signaling induced by guanabenz
and hypothesis that a member of the TRP channel family could be the target of
guanabenz.
The proﬁle of expression of TRPC and TRPV isoforms revealed the presence of
TRPC1, C6, V1, V2 and V3 in both CF-KM4 and CF15 cell lines. We demonstrated
that the guanabenz induced-response was inhibited by SKF, a TRPC family inhibitor
but not by Ruthenium Red, a TRPV family inhibitor. Moreover, we demonstrated
that a Small interfering RNA (SiRNA) TRPC6 transfection reduces by 45−50%
i) the expression of TRPC6 ii) the guanabenz-dependent Ca2+ inﬂux and iii) the
CaCC-dependent activity stimulated by guanabenz.
In conclusion, we demonstrated that TRPC6 could be considered as one of the
molecular target of guanabenz. However, it remains to study the possible involve-
ment of TRPC1 in guanabenz induced response. These results highlighted TRPC6
as a novel potential target to activate CaCC in CF human airway epithelial cells.
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